Subcutaneous interleukin-4 for relapsed non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.

被引：0
|
作者：
Kurtz, D. M. [1 ]
Tschetter, L. K. [1 ]
Allred, J. B. [1 ]
Geyer, S. M. [1 ]
Kurtin, P. J. [1 ]
Putnam, W. D. [1 ]
Rowland, K. M. [1 ]
Wiesenfeld, M. [1 ]
Soori, G. S. [1 ]
Tenglin, R. C. [1 ]
Bernath, A. M. [1 ]
Witzig, T. E. [1 ]
机构：
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2007年 / 55卷 / 02期
关键词：
D O I：
10.1097/00042871-200703010-00088
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
81
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 50 条
  • [21] A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
    Stopeck, Alison T.
    Unger, Joseph M.
    Rimsza, Lisa M.
    Bellamy, William T.
    Iannone, Maria
    Persky, Daniel O.
    Leblanc, Michael
    Fisher, Richard I.
    Miller, Thomas P.
    LEUKEMIA & LYMPHOMA, 2009, 50 (05) : 728 - 735
  • [22] Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma
    Allen, SL
    Schacter, LP
    Lichtman, SM
    Bukowski, R
    Fusco, D
    Hensley, M
    ODwyer, P
    Mittelman, A
    Rosenbloom, B
    Huybensz, S
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (02) : 213 - 217
  • [23] Phase II trial of docetaxel in non-Hodgkin's lymphomas: A study of the cancer and leukemia group B
    Budman, DR
    Petroni, GR
    Johnson, JL
    Cooper, MR
    Schlossman, DM
    Barcos, M
    Peterson, BA
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) : 3275 - 3279
  • [24] Primary central nervous system non-Hodgkin's lymphoma (PCNSL): Survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) study 86-72-52
    O'Neill, BP
    Wang, CH
    O'Fallon, JR
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (03): : 559 - 563
  • [25] Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108.
    Stopeck, AT
    Bellamy, W
    Unger, J
    Rimsza, L
    Iannone, M
    Fisher, RI
    Miller, TP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 583S - 583S
  • [26] Dexamethasone, cytarabine and oxaliplatin (DHAX) in relapsed or refractory non-Hodgkin's lymphoma patients: Results of an ongoing phase II trial.
    Chau, I
    Cunningham, D
    Hill, M
    Catovsky, D
    BLOOD, 2000, 96 (11) : 140A - 140A
  • [27] Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
    Varterasian, ML
    Mohammad, RM
    Shurafa, MS
    Hulburd, K
    Pemberton, PA
    Rodriguez, DH
    Spadoni, V
    Eilender, DS
    Murgo, A
    Wall, N
    Dan, M
    Al-Katib, AM
    CLINICAL CANCER RESEARCH, 2000, 6 (03) : 825 - 828
  • [28] A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/refractory aggressive histology non-Hodgkin's lymphoma.
    Piliotis, EG
    Mangel, J
    Buckstein, R
    Imrie, K
    Spaner, D
    Reis, M
    Foden, C
    Boudreau, A
    Richardson, P
    Richardson, J
    Berinstein, N
    BLOOD, 2003, 102 (11) : 288B - 288B
  • [29] Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Fayad, Luis
    Liebmann, James
    Modiano, Manuel
    Cohen, Gary
    Pro, Barbara
    Romaguera, Jorge
    Stromatt, Scott
    BLOOD, 2006, 108 (11) : 781A - 781A
  • [30] Gemcitabine and docetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma (HCC), a North Central Cancer Treatment Group (NCCTG) phase II trial
    Kim, GP
    Alberts, SR
    Tschetter, LK
    Fitch, TR
    Dakhil, SR
    Morlan, BW
    Sargent, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 380S - 380S
12345